Navigation Links
New Deloitte Recap Report Identifies Strategies to Help Reduce Development Times and Increase Success Rates for Cancer Drugs

SAN FRANCISCO, Nov. 2, 2010 /PRNewswire/ -- Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion in oncology drugs while transforming the medical outlook for many cancer patients.

"Scientific innovation has brought measurable rewards such as reduced development times, higher success rates for cancer drugs, and increased investment and activity across the biopharmaceutical industry," said Lisa Natanson, senior analyst, Deloitte Recap LLC. "We see clear patterns of successful drug development from this study of a defined set of biotechnology companies that have produced innovative cancer drugs in the last decade."

By analyzing the drug development patterns of the Deloitte Recap BioPortfolio Index (RBI) companies, a select group of more than 150 biotechnology companies that have been tracked and benchmarked for more than a decade, Deloitte identified the following key findings:

  • FDA-approved oncology compounds all heavily utilized at least one (and some as many as four) special U.S. regulatory mechanisms, such as Fast Track designation, Orphan Drug status, or Accelerated Approval, to speed clinical development and reduce FDA transit times.
  • Orphan indications served as an initial market entry point to billion dollar markets followed by label expansion efforts to broaden the patient populations.
  • Innovative agents, such as those targeting receptor tyrosine kinases, achieved up to 31 percent approval success rates.

"Overall, the findings of this report demonstrate that the biotech industry is having a measurable impact on developing new therapies in the 'war on cancer,'" concluded Matthew Hudes, national managing principal of the biotechnology practice for Deloitte Consulting LLP.

To register for a copy of this report, visit

About Deloitte Recap

Deloitte Recap LLC was originally founded as Recombinant Capital, Inc. in 1988 by Mark Edwards and based in the San Francisco Bay Area.  In July 2008, Recombinant Capital, Inc. was purchased by a subsidiary of Deloitte LLP and the business is now known as Deloitte Recap LLC.  

As used in this document, "Deloitte" means Deloitte LLP and its subsidiaries.   Please see for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

SOURCE Deloitte
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DUSA Pharmaceuticals Named to Deloittes 2010 Technology Fast 500 List of Fastest Growing Companies in North America
2. Virtual Radiologic Ranked 264th Fastest-Growing Company in North America on Deloittes 2010 Technology Fast 500™
3. China Medical Technologies Announces its Subsidiary, GP Medical, Ranked Sixth in Deloitte Technology Fast 50 China 2010 Program
4. Accuray Ranked Number 113 Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
5. Genoptix Ranked 41st Fastest-Growing Company in North America on Deloittes 2010 Technology Fast 500™
6. Deloitte Issue Brief: Mobile Personal Health Records May Offer Consumers Key to Technology-Enabled Self-Care
7. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
8. Time to Blow Up the Pharmaceutical Sales Model? New Deloitte Debate
9. Health Care Retail Clinics Continue Gradual Expansion Through 2012: Deloitte Center for Health Solutions Report
10. Deloitte Recap Launches New Solution for Clinical Development
11. Deloitte Report: Pharmaceutical Companies Patent Cliff Could Bolster Mergers and Acquisitions
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. ... ... ... ... Astellas is a ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):